Brokerages expect that Antares Pharma Inc (NASDAQ:ATRS) will announce $14.80 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Antares Pharma’s earnings. The highest sales estimate is $17.30 million and the lowest is $12.11 million. Antares Pharma posted sales of $14.20 million in the same quarter last year, which would indicate a positive year over year growth rate of 4.2%. The firm is scheduled to report its next earnings report on Tuesday, March 13th.
On average, analysts expect that Antares Pharma will report full-year sales of $14.80 million for the current fiscal year, with estimates ranging from $52.58 million to $58.20 million. For the next fiscal year, analysts anticipate that the business will report sales of $77.33 million per share, with estimates ranging from $64.00 million to $101.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The business had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.01 million. Antares Pharma’s revenue for the quarter was up 11.9% on a year-over-year basis.
Antares Pharma (ATRS) traded up $0.10 during trading hours on Tuesday, reaching $2.06. The company’s stock had a trading volume of 1,550,772 shares, compared to its average volume of 987,031. Antares Pharma has a 1 year low of $1.58 and a 1 year high of $4.09. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $322.20, a PE ratio of -18.73 and a beta of 0.30.
Large investors have recently bought and sold shares of the business. Capital Advantage Inc. acquired a new position in Antares Pharma in the third quarter valued at about $110,000. Alliancebernstein L.P. acquired a new position in Antares Pharma in the second quarter valued at about $119,000. Legal & General Group Plc acquired a new position in Antares Pharma in the second quarter valued at about $120,000. First Eagle Investment Management LLC grew its stake in Antares Pharma by 150.0% in the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock valued at $162,000 after acquiring an additional 30,000 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Antares Pharma in the second quarter valued at about $174,000. 34.88% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2018/02/09/antares-pharma-inc-atrs-expected-to-announce-quarterly-sales-of-14-80-million.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.